Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
In a recent review published in Signal Transduction and Targeted Therapy, researchers presented recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. Study: ...
Lexeo Therapeutics, Inc., a clinical-stage genetic medicine company focused on cardiovascular disease treatments, announced that it will present new data on its AAV manufacturing approach at the 28th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results